Drug intelligence / Profile preview

PST-674

Development stage: Unknown
Lead developer: Pharmasum Therapeutics
Modality: Small Molecules
Administration: Unspecified, Oral

Overview

PST-674 is a small molecule inhibitor of Dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), currently under development by Pharmasum Therapeutics. DYRK1A is a kinase encoded on chromosome 21, and its overexpression is a primary driver of cognitive impairment and neurodegeneration in individuals with Down syndrome and Alzheimer's disease. By inhibiting DYRK1A, PST-674 aims to modulate the phosphorylation of tau and amyloid precursor protein (APP), potentially slowing the progression of dementia. The compound is designed to be brain-penetrant and is being advanced into clinical development for Down syndrome-related dementia, Alzheimer's disease, and Parkinson's disease dementia.

Targets

DYRK1A (Dual-specificity tyrosine-phosphorylation-regulated kinase 1A)

Beyond the preview

Go deeper on PST-674.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PST-674.

Explore the full profile